CD8A and central nervous system cancer: Since a variety of immunological defects have been found, including decreased T cell numbers and impaired T cell responsiveness [36], the adoptive transfer of in vitro activated and expanded tumor-specific CD8+ T cells seems to be the most appropriate choice for treating glioma patients.